| 查看: 4442 | 回复: 178 | |||
| 【有奖交流】积极回复本帖子，参与交流，就有机会分得作者 geniusma 的 22 个金币 ，回帖就立即获得 1 个金币，每人有 1 次机会 | |||
[交流]
Call for Papers: SCI杂志 PPAR Research (IF: 2.93) Special Issue约稿!
|
|||
|
SCI杂志PPAR Research (IF: 2.93)特刊PPARs and Their Coactivators in Obesity and Metabolic Disease 约稿啦！ 本人和美国团队受邀作为special issue编辑开一期特刊。 杂志这几年影响因子稳步上升，今年很可能过3分！PPAR及其辅激活蛋白在代谢相关疾病，包括肿瘤中的机制和治疗均可！ Open Access期刊仁者见仁，智者见智，接近3分的PPAR Research (中科院三区) 质量还是不错的。 https://www.hindawi.com/journals/PPAR/si/812927/cfp/ 欢迎投稿！欢迎转发！ PPARs and Their Coactivators in Obesity and Metabolic Disease Call for Papers Peroxisome proliferator-activated receptors (PPARs) are a subfamily of ligand-inducible nuclear hormone receptors including PPARα (NR1C1), PPARβ/δ (NR1C2), and PPARγ (NR1C3), which have distinct tissue distribution and specific functions in response to their agonists. PPARs have been recognized as master regulators of a number of physiological processes in multiple organs and cell types, participating in cellular differentiation, development, carbohydrate and lipid metabolism, energy homeostasis, tumorigenesis, and inflammation. Given that PPARs are known to play central functions in metabolic homeostasis, highly effective PPAR agonists have been developed and are widely used for the treatment of chronic metabolic diseases. Upon specific ligand-binding, PPARs heterodimerize with the retinoid X receptor (RXR) and bind to the peroxisome proliferator responsive element (PPRE) on target genes. Importantly, the transcriptional activation of specific target genes set in motion by liganded PPARs is also determined by a number of coactivators that partner with PPARs in a tissue- and cell type-specific manner. Three major categories of PPAR coactivators have been identified: (1) those with chromatin remodeling effects, such as those carrying histone acetyltransferase (HAT) or methyltransferase activity (i.e., members of the p160/SRC family); (2) anchoring coactivators, which serve as linkers between cofactor complexes and the basal transcriptional machinery (i.e., members of the mediator complex); (3) coactivators without intrinsic enzymatic activity which function by providing a scaffold to aggregate large transcriptional complexes on tissue specific target genes: these cofactors include PGC1 family members among others. These coactivators have also been shown to be recruited in response to ligand/agonist activation to a number of nuclear receptors and transcriptional factors in addition to PPARs. As one of the most serious public health problems of the 21st century, obesity is mainly caused by the combination of excessive caloric intake, sedentary lifestyle, and genetic susceptibility. Obesity is the leading risk factor for many physical disorders commonly known as the metabolic disease/syndrome which includes but is not limited to type 2 diabetes, hypertension, hyperlipidemia, cardiovascular diseases, hepatic steatosis, and certain types of cancer ultimately reducing life expectancy. Thus, understanding the molecular basis of PPARs and coactivator functions in controlling the expression of selective gene programs may be helpful for the development of possible strategies to prevent/treat obesity and metabolic comorbidities. We invite investigators to submit original research articles and review articles that aim to increase our knowledge on the molecular basis of the effects of PPARs and of cofactors on metabolism and on energy homeostasis, in a PPAR dependent or independent manner. Studies describing strategies targeting PPARs and cofactors to prevent/treat obesity and metabolic diseases are also highly welcomed. Potential topics include but are not limited to the following: Role of PPARs and cofactors (a) in energy homeostasis and metabolic disease, including obesity, type 2 diabetes, hypertension, hyperlipidemia, cardiovascular diseases, hepatic steatosis, and chronic inflammation; (b) in certain types of cancer and aging-related diseases; (c) in adipocyte biology Role of noncoding RNAs in the regulation of PPARs and cofactors in homeostasis and metabolic disease Epigenetic modifications of PPARs and cofactors affecting homeostasis and metabolic disease Mechanisms of preferential recruitment of cofactors to PPARs to specify lipid storage and thermogenic gene programs, under certain physiological conditions New PPARs ligands and/or cofactors agonists as therapeutic agents for metabolic diseases Novel strategies targeting PPARs and cofactors for preventing/treating metabolic disease Authors can submit their manuscripts through the Manuscript Tracking System at https://mts.hindawi.com/submit/journals/ppar/comd/. Manuscript Due Friday, 2 June 2017 First Round of Reviews Friday, 25 August 2017 Publication Date Friday, 20 October 2017 Lead Guest Editor Xinran Ma, East China Normal University, Shanghai, China Guest Editors Lingyan Xu, East China Normal University, Shanghai, China Elisabetta Mueller, New York University, New York, USA |
回复此楼» 猜你喜欢
323求调剂
已经有6人回复
-
一志愿北京化工大学 070300 学硕 336分 求调剂
已经有4人回复
-
352求调剂
已经有3人回复
-
一志愿东华大学化学070300，求调剂
已经有8人回复
-
277材料科学与工程080500求调剂
已经有7人回复
-
317求调剂
已经有18人回复
-
293求调剂
已经有5人回复
-
280分求调剂 一志愿085802
已经有7人回复
-
0854电子信息求调剂
已经有3人回复
-
263求调剂
已经有4人回复
» 抢金币啦！回帖就可以得到:
-
绍兴大学博士教师招聘1位（化学化工相关）
+5/260
-
招收调剂生，动物医学专业
+1/84
-
化学化工学院 招收化工、化学、材料等相关方向研究生（学硕、专硕都有调剂名额）
+1/83
-
招收材料与化学相关专业硕士研究生
+1/81
-
双一流南京医科大学招计算机、AI、统计、生物信息等方向26年9月入学博士
+1/80
-
欢迎交流咨询
+1/42
-
2026 物理方向招收部分调剂
+1/33
-
1
+1/31
-
春眠不觉晓
+1/23
-
南医大基础医学院招收调剂生（2生信1生物））
+1/18
-
海南师范大学孙元元老师招生博士，名额1~2个，2026年9月份入学（光电/光热催化方向）
+1/17
-
江西赣州-赣南师范大学-学校推荐
+1/7
-
286求调剂
+1/6
-
26年申博自荐-计算机视觉
+1/5
-
宁波东方理工大学余鹏课题组2026年上海交大联培博士生、博士后、科研助理招聘
+1/4
-
欢迎生物与医药、药学、化学等相关专业的同学
+1/3
-
上海交通大学纳微能源创新平台博士研究生招生简章
+1/3
-
2026考研的同学，分数不够？想调剂上岸的同学，来看
+1/2
-
招收调剂生 国家重点实验室（广西某师范大学、B区）
+1/2
-
“机械、材料”招生
+1/1
9楼2016-12-27 21:25:23
32楼2016-12-27 22:22:53
简单回复
2016-12-27 20:55
回复
JOEF3楼
2016-12-27 21:01
回复
geniusma(金币+1): 谢谢参与
2016-12-27 21:04
回复
geniusma(金币+1): 谢谢参与
2016-12-27 21:17
回复
2016-12-27 21:21
回复
geniusma(金币+1): 谢谢参与
2016-12-27 21:22
回复
geniusma(金币+1): 谢谢参与
tan9148楼
2016-12-27 21:23
回复
geniusma(金币+1): 谢谢参与
paperhunter10楼
2016-12-27 21:25
回复
geniusma(金币+1): 谢谢参与
103062354311楼
2016-12-27 21:28
回复
geniusma(金币+1): 谢谢参与
多啦C梦060112楼
2016-12-27 21:31
回复
geniusma(金币+1): 谢谢参与
chejiacun13楼
2016-12-27 21:33
回复
geniusma(金币+1): 谢谢参与
lvluohua92914楼
2016-12-27 21:37
回复
geniusma(金币+1): 谢谢参与
三八洲15楼
2016-12-27 21:41
回复
geniusma(金币+1): 谢谢参与
icebergwu16楼
2016-12-27 21:44
回复
geniusma(金币+1): 谢谢参与
zuiaixuexi17楼
2016-12-27 21:45
回复
geniusma(金币+1): 谢谢参与
好
超级老快18楼
2016-12-27 21:47
回复
geniusma(金币+1): 谢谢参与
。 发自小木虫Android客户端
yexuqing19楼
2016-12-27 21:47
回复
geniusma(金币+1): 谢谢参与
祝福 发自小木虫Android客户端
longwave20楼
2016-12-27 21:50
回复
geniusma(金币+1): 谢谢参与
祝福 发自小木虫Android客户端
gengxin6021楼
2016-12-27 21:52
回复
geniusma(金币+1): 谢谢参与
吸血人狼城22楼
2016-12-27 21:56
回复
假大空23楼
2016-12-27 21:57
回复
geniusma(金币+1): 谢谢参与
顶
sunjialin12324楼
2016-12-27 21:57
回复
geniusma(金币+1): 谢谢参与
。 发自小木虫Android客户端
bj200898925楼
2016-12-27 22:02
回复
geniusma(金币+1): 谢谢参与
腿哥帅26楼
2016-12-27 22:06
回复
纳米材料75327楼
2016-12-27 22:07
回复
geniusma(金币+1): 谢谢参与
qwertyupoiuy28楼
2016-12-27 22:07
回复
geniusma(金币+1): 谢谢参与
！ 发自小木虫Android客户端
ajingne129楼
2016-12-27 22:13
回复
小木木头嘎达30楼
2016-12-27 22:14
回复
西北狼东北虎31楼
2016-12-27 22:17
回复
落花剑雨33楼
2016-12-27 22:26
回复
geniusma(金币+1): 谢谢参与
鱼儿123434楼
2016-12-27 22:27
回复
geniusma(金币+1): 谢谢参与
。 发自小木虫Android客户端
34868356935楼
2016-12-27 22:28
回复
hzk2zd36楼
2016-12-27 22:32
回复
geniusma(金币+1): 谢谢参与
牛 发自小木虫Android客户端
nono200937楼
2016-12-27 22:33
回复
geniusma(金币+1): 谢谢参与
`
syhorchid38楼
2016-12-27 22:36
回复
geniusma(金币+1): 谢谢参与
spc0839楼
2016-12-27 22:38
回复
geniusma(金币+1): 谢谢参与
dsctg40楼
2016-12-27 22:39
回复
geniusma(金币+1): 谢谢参与
sunjump41楼
2016-12-27 22:49
回复
geniusma(金币+1): 谢谢参与
vox70742楼
2016-12-27 22:59
回复
geniusma(金币+1): 谢谢参与
huzhang0143楼
2016-12-27 23:11
回复
geniusma(金币+1): 谢谢参与
OK 发自小木虫IOS客户端
xjd201444楼
2016-12-27 23:27
回复
1839482278645楼
2016-12-27 23:35
回复
chentao46楼
2016-12-27 23:41
回复
geniusma(金币+1): 谢谢参与
wtbccq50547楼
2016-12-27 23:43
回复
geniusma(金币+1): 谢谢参与
tableman48楼
2016-12-27 23:45
回复
geniusma(金币+1): 谢谢参与
祝福了。
nbjiuxu49楼
2016-12-27 23:55
回复
LifePursuit50楼
2016-12-27 23:56
回复
geniusma(金币+1): 谢谢参与
一 发自小木虫IOS客户端
